Pharmafile Logo
Pharmafocus logo
Advanced Search
gilead-sciences

Gilead’s CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma

December 3, 2018
Research and Development, Sales and Marketing ASH 2-18, CAR-T, Cancer, Gilead, Yescarta, leukaemia, pharma

Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the …

News

GSK to acquire oncology biotech Tesaro for $5.1 billion

December 3, 2018
Sales and Marketing GSK, GlaxoSmtihKline, Tesaro, acquisition, oncology, pharma

GlaxoSmithKline is set to acquire US-based oncology biotech Tesaro after both companies signed a definitive agreement with an aggregate cash …

News
abbvie_0

AbbVie’s Venclyxto combo beats standard of care in chronic lymphocytic leukaemia

December 3, 2018
Research and Development, Sales and Marketing ASH 2018, AbbVie, Cancer, Venclyxto, leukaemia, pharma

AbbVie has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to reveal new data on …

News

Novartis unveils strong longer-term Kymriah data at ASH 2018

December 3, 2018
Research and Development, Sales and Marketing ASH 2018, Cancer, Kymriah, Novartis, leukaemia, pharma

Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah (tisagenlecleucel) at the American Society of …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

November 30, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, Immuno Biotech, NHS, Roche, autism, biosimilars, pharma, top ten

We’ve come to the end of November, and with only one month of the year left to go, the industry …

News
opdivo_1_1

Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund

November 30, 2018
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, NICE, UK, melanoma, pharma

Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer …

News
merckwindow_web

MSD chalks up two HIV drug approvals in Europe

November 30, 2018
Medical Communications, Sales and Marketing Delstrigo, EU, Europe, HIV, MSD, Pifeltro, pharma

MSD has announced the European approval of two of its products for the treatment of HIV: the single-tablet combination Delstrigo …

News
brexit_flag

83% in healthcare say UK will not be attractive for R&D and manufacturing post-Brexit

November 30, 2018
Medical Communications, Research and Development R&D, UK, brexit, pharma

As the Brexit crisis continues to spiral, new findings from GlobalData reveal that 83% of healthcare professionals in the UK …

News

Bayer announces major restructure, 12,000 jobs to go

November 30, 2018
Medical Communications, Sales and Marketing Bayer, job cuts, monsanto, pharma

Bayer has announced a major restructure of its operations in 2019 which will see the loss of 12,000 of its …

News

UK is among the first to meet UN targets for HIV treatment and prevention, Public Health England says

November 29, 2018
Medical Communications HIV, UK, pharma

The UK is among the first countries in the world to meet the HIV treatment targets set out by the …

News

Astellas’ Xospata becomes US-approved drug for FLT3-mutated acute myeloid leukaemia

November 29, 2018
Sales and Marketing Astellas, FDA, US, Xospata, acute myeloid leukamia

Astellas has revealed that Xospata (gilteritinib) has been awarded FDA approval as a treatment for relapsed or refractory acute myeloid …

News

FDA approves first Rituxan biosimilar courtesy of Teva and Celltrion

November 29, 2018
Sales and Marketing FDA, Genentech, Rituxan, Roche, Teva, Truxima, biosimilars, celltrion

The FDA has announced the first US approval of a biosimilar version of Genentech’s Rituxan (rituximab), awarding marketing approval to …

News

Novartis’ Gilenya scores paediatric EU approval for advanced relapsing-remitting MS

November 29, 2018
Sales and Marketing Europe, Novartis, UK, multiple sclerosis, pharma

Novartis has announced that Gilenya (fingolimod) has received marketing authorisation from the European Commission for the treatment of relapsing-remitting forms …

News

NICE recommends Bayer’s Stivarga for advanced hepatocellular carcinoma

November 29, 2018
Sales and Marketing Bayer, NICE, Stivarga, UK, pharma

The National Institute for Health and Care Excellence (NICE) has voiced its recommendation for Bayer’s Stivarga (regorafenib) for use on …

News
genentech_web

Roche’s Genentech to acquire inflammatory drug discovery firm Jecure

November 28, 2018
Research and Development, Sales and Marketing Genentech, Jecure, Roche, liver disease, nash, pharma

Roche’s subsidiary Genentech has finalised a definitive agreement to acquire Jecure, a US-based biotech which focuses on the discovery of …

News
shutterstock_204190579

UK cervical cancer screening rates fall to 21-year low

November 28, 2018
Medical Communications, Research and Development Cancer, NHS, UK, cervical cancer, pharma

A report by NHS Digital has revealed that cervical cancer screening coverage has fallen to 71.4%, down from 72% in …

News
epipen

Teva’s EpiPen generic retails for same price as Mylan’s own

November 28, 2018
Research and Development, Sales and Marketing Mylan, Teva, epipen, pharma

Israeli generics firm Teva has revealed the price tag of its generic version of Mylan’s EpiPen epinephrine auto-injector, and, at …

News
bayercross3

Bayer’s Jivi approved in Europe for previously treated haemophilia A

November 28, 2018
Research and Development, Sales and Marketing Bayer, Jivi, haemophilia, pharma

Bayer has revealed that its recombinant Factor VIII (rFVIII) replacement therapy Jivi, also known as BAY94-9027, has received approval from …

News
takeda_usa_pharmaceuticals_u

European approval for Takeda’s Alunbrig in ALK+ advanced non-small cell lung cancer

November 27, 2018
Research and Development, Sales and Marketing Alunbrig, Cancer, Takeda, lung cancer, pharma

Takeda’s Alunbrig (brigatinib) has been granted marketing approval by the European Commission as a monotherapy to treat anaplastic lymphoma kinase-positive …

News
shutterstock_87495637

Pegfilgrastim greenlight marks eighth biosimilar approval in Europe for Sandoz

November 27, 2018
Manufacturing and Production, Sales and Marketing Amgen, Neulasta, Sanofi, Ziextenzo, biosimilars, pegfilgrastim, pharma

The European Commission has chosen to grant marketing authorisation to Ziextenzo, Sandoz’s biosimilar version of pegfilgrastim, better known as Amgen’s …

News
The Gateway to Local Adoption Series

Latest content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

January 27, 2026

Crystalys Therapeutics appoints Justin Thacker as Chief Financial Officer

January 27, 2026

Rentschler Biopharma appoints Uwe Buecheler as interim CEO

January 26, 2026

Sandoz’ Ondibta receives European Commission approval for diabetes

January 26, 2026

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026